0.007928 0.000000 0.000000 0.000000 0.007928 0.000000 0.000000 0.000000 0.013253 0.00000 0.00000 0.00000 Petersen, J. Edman, K. Edfeldt, F. Johansson, C. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 16 90.00 90.00 90.00 126.143 126.143 75.454 C15 H11 N O 221.254 2-PHENYLQUINOLIN-4-OL non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Bioorg.Med.Chem.Lett. BMCLE8 1127 0960-894X 21 777 10.1016/J.BMCL.2010.11.110 21183345 Non-Covalent Inhibitors of Rhinovirus 3C Protease. 2011 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 SINGLE WAVELENGTH M x-ray 1 1.0 ESRF SYNCHROTRON ESRF 20125.793 PICORNAIN 3C 3.4.22.28 1 man polymer 221.254 2-PHENYLQUINOLIN-4-OL 1 syn non-polymer 18.015 water 30 nat water PROTEASE 3C, P3C, HUMAN RHINOVIRUS 3C PROTEASE no no GSGPEEEFGMSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLD RNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVL GIHVGGNGRDGFSAMLLRSYFT GSGPEEEFGMSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLD RNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVL GIHVGGNGRDGFSAMLLRSYFT A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n sample 169066 HUMAN RHINOVIRUS SP. 562 ESCHERICHIA COLI 3.73 67.01 NONE repository Initial release Version format compliance Version format compliance 1 0 2011-04-27 1 1 2011-05-08 1 2 2011-07-13 FAB FRAGMENT (ANTIBODY 8F5) COMPLEXED WITH PEPTIDE FROMHUMAN RHINOVIRUS (SEROTYPE 2) VIRAL CAPSID PROTEIN VP2(RESIDUES 156 - 170) TYPE 2 RHINOVIRUS 3C PROTEASE WITH AG7088 INHIBITOR 2A CYSTEINE PROTEINASE FROM HUMAN RHINOVIRUS 2 HUMAN RHINOVIRUS 2 BOUND TO A FRAGMENT OF ITS CELLULARRECEPTOR PROTEIN HUMAN RHINOVIRUS SEROTYPE 2 (HRV2) SHEET DETERMINATION METHOD: DSSP THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS BELOW IS ACTUALLY AN 6-STRANDED BARREL THIS IS REPRESENTED BY A 7-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS ARE IDENTICAL. PDBE Y PDBE 2010-11-16 REL 7L4 2-PHENYLQUINOLIN-4-OL HOH water 7L4 1181 2 7L4 7L4 1181 A HOH 2001 3 HOH HOH 2001 A HOH 2002 3 HOH HOH 2002 A HOH 2003 3 HOH HOH 2003 A HOH 2004 3 HOH HOH 2004 A HOH 2005 3 HOH HOH 2005 A HOH 2006 3 HOH HOH 2006 A HOH 2007 3 HOH HOH 2007 A HOH 2008 3 HOH HOH 2008 A HOH 2009 3 HOH HOH 2009 A HOH 2010 3 HOH HOH 2010 A HOH 2011 3 HOH HOH 2011 A HOH 2012 3 HOH HOH 2012 A HOH 2013 3 HOH HOH 2013 A HOH 2014 3 HOH HOH 2014 A HOH 2015 3 HOH HOH 2015 A HOH 2016 3 HOH HOH 2016 A HOH 2017 3 HOH HOH 2017 A HOH 2018 3 HOH HOH 2018 A HOH 2019 3 HOH HOH 2019 A HOH 2020 3 HOH HOH 2020 A HOH 2021 3 HOH HOH 2021 A HOH 2022 3 HOH HOH 2022 A HOH 2023 3 HOH HOH 2023 A HOH 2024 3 HOH HOH 2024 A HOH 2025 3 HOH HOH 2025 A HOH 2026 3 HOH HOH 2026 A HOH 2027 3 HOH HOH 2027 A HOH 2028 3 HOH HOH 2028 A HOH 2029 3 HOH HOH 2029 A HOH 2030 3 HOH HOH 2030 A GLY -1 n 1 GLY -1 A SER 0 n 2 SER 0 A GLY 1 n 3 GLY 1 A PRO 2 n 4 PRO 2 A GLU 3 n 5 GLU 3 A GLU 4 n 6 GLU 4 A GLU 5 n 7 GLU 5 A PHE 6 n 8 PHE 6 A GLY 7 n 9 GLY 7 A MET 8 n 10 MET 8 A SER 9 n 11 SER 9 A LEU 10 n 12 LEU 10 A ILE 11 n 13 ILE 11 A LYS 12 n 14 LYS 12 A HIS 13 n 15 HIS 13 A ASN 14 n 16 ASN 14 A SER 15 n 17 SER 15 A CYS 16 n 18 CYS 16 A VAL 17 n 19 VAL 17 A ILE 18 n 20 ILE 18 A THR 19 n 21 THR 19 A THR 20 n 22 THR 20 A GLU 21 n 23 GLU 21 A ASN 22 n 24 ASN 22 A GLY 23 n 25 GLY 23 A LYS 24 n 26 LYS 24 A PHE 25 n 27 PHE 25 A THR 26 n 28 THR 26 A GLY 27 n 29 GLY 27 A LEU 28 n 30 LEU 28 A GLY 29 n 31 GLY 29 A VAL 30 n 32 VAL 30 A TYR 31 n 33 TYR 31 A ASP 32 n 34 ASP 32 A ARG 33 n 35 ARG 33 A PHE 34 n 36 PHE 34 A VAL 35 n 37 VAL 35 A VAL 36 n 38 VAL 36 A VAL 37 n 39 VAL 37 A PRO 38 n 40 PRO 38 A THR 39 n 41 THR 39 A HIS 40 n 42 HIS 40 A ALA 41 n 43 ALA 41 A ASP 42 n 44 ASP 42 A PRO 43 n 45 PRO 43 A GLY 44 n 46 GLY 44 A LYS 45 n 47 LYS 45 A GLU 46 n 48 GLU 46 A ILE 47 n 49 ILE 47 A GLN 48 n 50 GLN 48 A VAL 49 n 51 VAL 49 A ASP 50 n 52 ASP 50 A GLY 51 n 53 GLY 51 A ILE 52 n 54 ILE 52 A THR 53 n 55 THR 53 A THR 54 n 56 THR 54 A LYS 55 n 57 LYS 55 A VAL 56 n 58 VAL 56 A ILE 57 n 59 ILE 57 A ASP 58 n 60 ASP 58 A SER 59 n 61 SER 59 A TYR 60 n 62 TYR 60 A ASP 61 n 63 ASP 61 A LEU 62 n 64 LEU 62 A TYR 63 n 65 TYR 63 A ASN 64 n 66 ASN 64 A LYS 65 n 67 LYS 65 A ASN 66 n 68 ASN 66 A GLY 67 n 69 GLY 67 A ILE 68 n 70 ILE 68 A LYS 69 n 71 LYS 69 A LEU 70 n 72 LEU 70 A GLU 71 n 73 GLU 71 A ILE 72 n 74 ILE 72 A THR 73 n 75 THR 73 A VAL 74 n 76 VAL 74 A LEU 75 n 77 LEU 75 A LYS 76 n 78 LYS 76 A LEU 77 n 79 LEU 77 A ASP 78 n 80 ASP 78 A ARG 79 n 81 ARG 79 A ASN 80 n 82 ASN 80 A GLU 81 n 83 GLU 81 A LYS 82 n 84 LYS 82 A PHE 83 n 85 PHE 83 A ARG 84 n 86 ARG 84 A ASP 85 n 87 ASP 85 A ILE 86 n 88 ILE 86 A ARG 87 n 89 ARG 87 A ARG 88 n 90 ARG 88 A TYR 89 n 91 TYR 89 A ILE 90 n 92 ILE 90 A PRO 91 n 93 PRO 91 A ASN 92 n 94 ASN 92 A ASN 93 n 95 ASN 93 A GLU 94 n 96 GLU 94 A ASP 95 n 97 ASP 95 A ASP 96 n 98 ASP 96 A TYR 97 n 99 TYR 97 A PRO 98 n 100 PRO 98 A ASN 99 n 101 ASN 99 A CYS 100 n 102 CYS 100 A ASN 101 n 103 ASN 101 A LEU 102 n 104 LEU 102 A ALA 103 n 105 ALA 103 A LEU 104 n 106 LEU 104 A LEU 105 n 107 LEU 105 A ALA 106 n 108 ALA 106 A ASN 107 n 109 ASN 107 A GLN 108 n 110 GLN 108 A PRO 109 n 111 PRO 109 A GLU 110 n 112 GLU 110 A PRO 111 n 113 PRO 111 A THR 112 n 114 THR 112 A ILE 113 n 115 ILE 113 A ILE 114 n 116 ILE 114 A ASN 115 n 117 ASN 115 A VAL 116 n 118 VAL 116 A GLY 117 n 119 GLY 117 A ASP 118 n 120 ASP 118 A VAL 119 n 121 VAL 119 A VAL 120 n 122 VAL 120 A SER 121 n 123 SER 121 A TYR 122 n 124 TYR 122 A GLY 123 n 125 GLY 123 A ASN 124 n 126 ASN 124 A ILE 125 n 127 ILE 125 A LEU 126 n 128 LEU 126 A LEU 127 n 129 LEU 127 A SER 128 n 130 SER 128 A GLY 129 n 131 GLY 129 A ASN 130 n 132 ASN 130 A GLN 131 n 133 GLN 131 A THR 132 n 134 THR 132 A ALA 133 n 135 ALA 133 A ARG 134 n 136 ARG 134 A MET 135 n 137 MET 135 A LEU 136 n 138 LEU 136 A LYS 137 n 139 LYS 137 A TYR 138 n 140 TYR 138 A SER 139 n 141 SER 139 A TYR 140 n 142 TYR 140 A PRO 141 n 143 PRO 141 A THR 142 n 144 THR 142 A LYS 143 n 145 LYS 143 A SER 144 n 146 SER 144 A GLY 145 n 147 GLY 145 A TYR 146 n 148 TYR 146 A CYS 147 n 149 CYS 147 A GLY 148 n 150 GLY 148 A GLY 149 n 151 GLY 149 A VAL 150 n 152 VAL 150 A LEU 151 n 153 LEU 151 A TYR 152 n 154 TYR 152 A LYS 153 n 155 LYS 153 A ILE 154 n 156 ILE 154 A GLY 155 n 157 GLY 155 A GLN 156 n 158 GLN 156 A VAL 157 n 159 VAL 157 A LEU 158 n 160 LEU 158 A GLY 159 n 161 GLY 159 A ILE 160 n 162 ILE 160 A HIS 161 n 163 HIS 161 A VAL 162 n 164 VAL 162 A GLY 163 n 165 GLY 163 A GLY 164 n 166 GLY 164 A ASN 165 n 167 ASN 165 A GLY 166 n 168 GLY 166 A ARG 167 n 169 ARG 167 A ASP 168 n 170 ASP 168 A GLY 169 n 171 GLY 169 A PHE 170 n 172 PHE 170 A SER 171 n 173 SER 171 A ALA 172 n 174 ALA 172 A MET 173 n 175 MET 173 A LEU 174 n 176 LEU 174 A LEU 175 n 177 LEU 175 A ARG 176 n 178 ARG 176 A SER 177 n 179 SER 177 A TYR 178 n 180 TYR 178 A PHE 179 n 181 PHE 179 A THR 180 n 182 THR 180 A author_and_software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N THR 54 A N THR 56 A O ILE 47 A O ILE 49 A N GLN 48 A N GLN 50 A O THR 19 A O THR 21 A N THR 20 A N THR 22 A O GLY 23 A O GLY 25 A N VAL 30 A N VAL 32 A O PHE 34 A O PHE 36 A N VAL 37 A N VAL 39 A O THR 73 A O THR 75 A N VAL 74 A N VAL 76 A O TYR 60 A O TYR 62 A N LEU 104 A N LEU 106 A O THR 112 A O THR 114 A N TYR 122 A N TYR 124 A O MET 135 A O MET 137 A N TYR 138 A N TYR 140 A O GLY 169 A O GLY 171 A N ALA 172 A N ALA 174 A O ILE 160 A O ILE 162 A N LEU 158 A N LEU 160 A O LEU 151 A O LEU 153 A N TYR 152 A N TYR 154 A O ASN 101 A O ASN 103 1 A HOH 2006 C HOH 1 A ASP 32 50.83 -124.75 1 A ASP 42 48.68 70.24 1 A GLU 71 89.89 15.22 1 A GLU 81 123.89 150.09 1 A ASN 99 46.42 72.73 1 A LEU 105 -125.72 -54.89 47.270 -1.43 0.00 0.00 -1.43 0.00 2.86 0.927 0.875 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. 0.28850 0.22719 0.22987 2.40 89.09 563 11202 4.8 96.36 7.376 0.175 RANDOM 1 THROUGHOUT OTHER 0.293 0.257 0.80 0.80 1.40 NONE MAXIMUM LIKELIHOOD BABINET MODEL WITH MASK 2.40 89.09 30 1462 17 0 1415 0.014 0.022 1461 2.158 1.987 1978 4.865 5.000 181 35.837 24.545 66 13.303 15.000 246 16.305 15.000 8 0.129 0.200 216 0.007 0.020 1125 0.216 0.200 575 0.315 0.200 992 0.134 0.200 62 0.145 0.200 21 0.112 0.200 5 0.972 1.500 919 1.706 2.000 1450 2.301 3.000 627 3.459 4.500 528 0.458 0.269 2.462 39 748 20 89.94 2.40 45.20 2XYA 12145 0.0 0.10 1 6.60 6.9 99.5 2.40 2.46 1 7.2 refinement REFMAC 5.2.0019 data reduction MOSFLM data scaling SCALA PICORNAIN 3C (E.C.3.4.22.28) Non-covalent inhibtors of rhinovirus 3C protease. 1 N N 2 N N 3 N N A GLY 1 A GLY 3 HELX_P A ASN 14 A ASN 16 1 1 14 A HIS 40 A HIS 42 HELX_P A ASP 42 A ASP 44 5 2 3 A ILE 86 A ILE 88 HELX_P A ILE 90 A ILE 92 5 3 5 A LYS 143 A LYS 145 HELX_P A CYS 147 A CYS 149 5 4 5 A LEU 175 A LEU 177 HELX_P A PHE 179 A PHE 181 5 5 5 HYDROLASE HYDROLASE, CYSTEINE PROTEASE A GLY -1 A GLY 1 1 A SER 0 A SER 2 -2.55 A SER 0 A SER 2 1 A GLY 1 A GLY 3 3.99 A ASN 80 A ASN 82 1 A GLU 81 A GLU 83 -3.41 POLG_HRV2 UNP 1 P04936 1508 1687 2XYA 1 180 P04936 A 1 3 182 1 expression tag GLY -1 2XYA A P04936 UNP 1 1 expression tag SER 0 2XYA A P04936 UNP 2 7 7 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A ILE 52 A ILE 54 A LYS 55 A LYS 57 A GLU 46 A GLU 48 A VAL 49 A VAL 51 A SER 15 A SER 17 A THR 20 A THR 22 A GLY 23 A GLY 25 A TYR 31 A TYR 33 A PHE 34 A PHE 36 A PRO 38 A PRO 40 A LYS 69 A LYS 71 A LYS 76 A LYS 78 A SER 59 A SER 61 A TYR 63 A TYR 65 A TYR 97 A TYR 99 A LEU 104 A LEU 106 A THR 112 A THR 114 A GLY 123 A GLY 125 A ARG 134 A ARG 136 A SER 139 A SER 141 A ASP 168 A ASP 170 A MET 173 A MET 175 A GLN 156 A GLN 158 A GLY 164 A GLY 166 A VAL 150 A VAL 152 A LYS 153 A LYS 155 A TYR 97 A TYR 99 A LEU 104 A LEU 106 BINDING SITE FOR RESIDUE 7L4 A 1181 Software 13 A LEU 126 A LEU 128 13 6_555 A LEU 127 A LEU 129 13 6_555 A SER 128 A SER 130 13 6_555 A GLY 129 A GLY 131 13 6_555 A THR 132 A THR 134 13 6_555 A THR 142 A THR 144 13 1_555 A LYS 143 A LYS 145 13 1_555 A SER 144 A SER 146 13 1_555 A HIS 161 A HIS 163 13 1_555 A VAL 162 A VAL 164 13 1_555 A GLY 163 A GLY 165 13 1_555 A GLY 164 A GLY 166 13 1_555 A GLY 166 A GLY 168 13 1_555 98 I 41 2 2